Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH

Rhea-AI Summary

Ribo and Madrigal (NASDAQ: MDGL) announced the first major milestone in their liver disease siRNA partnership: nomination of a candidate drug for MASH. This triggers immediate start of IND-enabling studies to support planned clinical trials.

The collaboration spans multiple preclinical liver-directed assets targeting significant unmet need in MASH.

Positive

• First siRNA candidate drug for MASH nominated within the Ribo–Madrigal partnership
• IND-enabling studies to begin immediately, moving the program toward clinical testing
• Collaboration covers multiple preclinical liver-directed assets, expanding MASH pipeline options
• Partnership combines Madrigal’s MASH clinical expertise with Ribo’s siRNA discovery capabilities

Negative

• All partnership assets remain preclinical, with human clinical data still pending

News Market Reaction – MDGL

+2.67%

+2.67% Session close to close

In the Jul 2 session, MDGL gained 2.67%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The nomination of a first siRNA candidate for MASH expands Madrigal’s liver disease pipeline alongsi...

Analysis

The nomination of a first siRNA candidate for MASH expands Madrigal’s liver disease pipeline alongside existing data on Rezdiffra. Investors may weigh this early-stage upside against development risk and already-elevated short positioning when tracking future trial progress.

Historical Context

5 past events · Latest: Jun 22 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 22	Equity inducement awards	Neutral	+0.1%	Granted 1,397 time-based RSUs to five new non-executive employees.
Jun 04	Equity inducement awards	Neutral	-1.2%	Granted 6,881 time-based RSUs to 20 new non-executive employees.
Jun 03	Conference participation	Neutral	+7.8%	Announced participation in 47th Annual Goldman Sachs Health Care Conference.
May 27	Clinical data update	Positive	+0.7%	Reported Phase 3 and real-world data on Rezdiffra in MASH patients.
May 21	Equity inducement awards	Neutral	+0.7%	Granted 5,308 restricted stock units to 15 new non-executive employees.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news items, including conference participation, data updates and compensation actions, have generally produced mild to moderate positive moves, with only one small negative reaction.

Key Terms

sirna, ind-enabling, metabolic dysfunction-associated steatohepatitis, rna therapeutics

4 terms

sirna medical

"their siRNA partnership."

Small interfering RNA (siRNA) is a short strand of genetic material that binds to and destroys the messenger RNA that carries instructions for making a specific protein, effectively switching that gene off. Investors care because siRNA is a platform for precise medicines: successful trials or approvals can create high-value drugs, while delivery challenges, manufacturing complexity, patent positions and regulatory risk can sharply affect a biotech company's prospects.

ind-enabling regulatory

"followed by immediate initiation of IND-enabling studies to support planned clinical studies."

Ind-enabling describes the preclinical tests and safety work a drug candidate must pass before a company can ask regulators for permission to start human trials (an Investigational New Drug or IND filing). Think of it as the mechanical inspection and crash-testing a prototype car needs before it can legally be driven on public roads; for investors, successful ind-enabling work reduces technical and regulatory risk and makes clinical progress and potential value creation more likely.

metabolic dysfunction-associated steatohepatitis medical

"with a primary focus on metabolic dysfunction-associated steatohepatitis (MASH), a field"

Metabolic dysfunction-associated steatohepatitis is a liver disease in which fat buildup tied to metabolic problems such as obesity and diabetes leads to inflammation and scarring, like rust forming inside a machine that gradually impairs function. It matters to investors because its growing prevalence creates large markets for drugs, diagnostics and care, and clinical trial results, approvals, or reimbursement decisions can sharply change the value of healthcare companies working in this area.

rna therapeutics medical

"joint commitment to advancing cutting-edge RNA therapeutics for liver diseases,"

RNA therapeutics are medicines that use snippets of genetic instructions called RNA to change what proteins cells make, either by turning off harmful proteins, restoring missing ones, or teaching cells to make new proteins. Investors care because these treatments can target diseases that were hard to treat before, offering potential for big revenues but also carrying development, manufacturing and regulatory risk similar to a software update that promises major new features but may take time and testing to work reliably.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SUZHOU, China and MÖLNDAL, Sweden, July 1, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo"), in collaboration with Madrigal Pharmaceuticals, Inc. (Madrigal, NASDAQ: MDGL) announce the successful achievement of the first candidate drug nomination milestone within their siRNA partnership. This milestone is the result of efficient collaboration and will be followed by immediate initiation of IND-enabling studies to support planned clinical studies.

This partnership fully underscores Ribo's and Madrigal's joint commitment to advancing cutting-edge RNA therapeutics for liver diseases, with a primary focus on metabolic dysfunction-associated steatohepatitis (MASH), a field with tremendous unmet medical need. The collaboration covers multiple preclinical assets and further broadens the potential liver-directed therapeutic landscape for MASH.

"We are delighted to achieve the first key milestone in our joint MASH program with Madrigal in just a few months. Madrigal has established a market leading presence and profound clinical expertise in the MASH field, while Ribo possesses world-class capabilities in siRNA drug discovery and delivery technology.  Our complementary strengths have driven the rapid progress of this project. Both parties are dedicated to accelerating the development of our novel siRNA candidate for MASH. We look forward to advancing this collaborative program together and bringing promising new therapeutic options to patients worldwide living with MASH," said Li-Ming Gan, co-CEO & Global R&D President of Ribo.

About Suzhou Ribo Life Science Co. Ltd. and Ribocure Pharmaceuticals AB
Suzhou Ribo Life Science Co. Ltd. (Ribo, 06938.HK) is an innovative clinical stage R&D company devoted to the development of nucleic acid drugs and related products based on the RNA interference (RNAi) technology. With its innovative R&D capabilities with vertically integrated technological platforms, Ribo has built a strong product pipeline, aiming to make contribution to the treatment of serious diseases with unmet medical needs.
As a subsidiary of Suzhou Ribo Life Science, Ribocure Pharmaceuticals AB (Ribocure) is dedicated to globalized development of life-saving oligonucleotide therapies, with focus on development of assets and pipeline as well as new target ideas and on building innovative capacities to conduct clinical trials and developing siRNA drugs to address real unmet medical needs globally.
For more information, please visit www.ribolia.com and www.ribocure.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ribo-and-madrigal-reach-first-major-milestone-in-advancing-novel-sirna-therapies-for-mash-302816515.html

SOURCE Suzhou Ribo Life Science Co., Ltd.

FAQ

What milestone did Ribo and Madrigal (NASDAQ: MDGL) announce in their MASH siRNA partnership?

Ribo and Madrigal announced nomination of the first siRNA candidate drug for MASH. According to the companies, this marks the first major milestone in their collaboration and supports progression toward regulatory submissions and planned clinical development.

How does the Ribo and Madrigal MASH collaboration use siRNA technology?

The collaboration applies siRNA technology to develop liver-directed therapies for MASH. According to the companies, Ribo contributes siRNA discovery and delivery capabilities, while Madrigal adds clinical experience in MASH to advance novel RNA-based metabolic liver disease treatments.

What are the next steps after Ribo and Madrigal’s MASH siRNA candidate nomination?

The next step is to start IND-enabling studies for the nominated siRNA candidate. According to the companies, these preclinical studies aim to generate data needed to support planned clinical trials in patients with metabolic dysfunction-associated steatohepatitis.

Does the Ribo and Madrigal (MDGL) MASH partnership include multiple siRNA assets?

Yes, the partnership covers multiple preclinical siRNA assets targeting liver diseases, with a focus on MASH. According to the companies, this broader pipeline may expand liver-directed therapeutic options beyond the first nominated candidate drug.

Why is the Ribo and Madrigal siRNA program important for patients with MASH?

The program targets MASH, a liver disease with substantial unmet medical need. According to the companies, advancing novel siRNA therapies could provide additional treatment options for patients worldwide if future clinical trials and regulatory reviews are successful.

What strengths do Ribo and Madrigal each bring to their MASH siRNA collaboration?

Madrigal contributes market presence and clinical expertise in MASH, while Ribo offers siRNA discovery and delivery technology. According to the companies, these complementary strengths have helped achieve the first milestone within months and support faster development of the MASH candidate.